View in EDS

Affinity-matured CD72-targeting nanobody CAR T cells enhance elimination of antigen-low B-cell malignancies.

Saved in:
Bibliographic Details
Title: Affinity-matured CD72-targeting nanobody CAR T cells enhance elimination of antigen-low B-cell malignancies.
Authors: Izgutdina A; Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA., Rashid T; Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA., Temple WC; Department of Pediatrics, Division of Oncology, UCSF Benioff Children's Hospital, University of California San Francisco, San Francisco, California, USA.; Department of Pediatrics, Division of Allergy, Immunology, and Bone Marrow Transplantation, UCSF Benioff Children's Hospital, University of California San Francisco, San Francisco, California, USA., Aminov S; Department of Oncology, Blood Cancer Institute, Albert Einstein College of Medicine, Bronx, New York, USA., Patiño-Escobar B; Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA., Walunj S; Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA., Geng H; Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA., Takamatsu H; Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA.; Department of Hematology, Kanazawa University, Kanazawa, Japan., Gil-Alós D; Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA.; Hospital Universitario 12 de Octubre-Centro Nacional de Investigaciones Oncológicas (H12O-CNIO) Haematological Malignancies Clinical Research Unit, Spanish National Cancer Research Centre, Madrid, Spain.; Department of Hematology, Hospital Universitario 12 de Octubre-Universidad Complutense, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), CIBERONC, Madrid, Spain., Kang AS; Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA., Ramos E; Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA., Chen SY; Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA., Johnson H; Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA., Nix MA; Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA., Naik A; Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA., Li M; Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA., Yuan CM; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA., Wang HW; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA., Sahu S; Department of Oncology, Blood Cancer Institute, Albert Einstein College of Medicine, Bronx, New York, USA., Larson RC; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA., Carpenter C; Arc Institute, Palo Alto, California, USA., Salangsang F; Preclinical Therapeutics Core, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA., Phojanakong P; Preclinical Therapeutics Core, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA., Serrano JAC; Preclinical Therapeutics Core, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA., Tariq I; Preclinical Therapeutics Core, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA., Zakraoui O; Preclinical Therapeutics Core, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA., Steri V; Preclinical Therapeutics Core, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA., Valeri A; Hospital Universitario 12 de Octubre-Centro Nacional de Investigaciones Oncológicas (H12O-CNIO) Haematological Malignancies Clinical Research Unit, Spanish National Cancer Research Centre, Madrid, Spain.; Department of Hematology, Hospital Universitario 12 de Octubre-Universidad Complutense, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), CIBERONC, Madrid, Spain., Martinez-Lopez J; Hospital Universitario 12 de Octubre-Centro Nacional de Investigaciones Oncológicas (H12O-CNIO) Haematological Malignancies Clinical Research Unit, Spanish National Cancer Research Centre, Madrid, Spain.; Department of Hematology, Hospital Universitario 12 de Octubre-Universidad Complutense, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), CIBERONC, Madrid, Spain., Maus MV; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA.; Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, Massachusetts, USA., Parekh S; Department of Medicine, Division of Hematology and Medical Oncology; Department of Oncological Sciences; and Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Verma A; Department of Oncology, Blood Cancer Institute, Albert Einstein College of Medicine, Bronx, New York, USA., Shah NN; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA., Wiita AP; Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA arun.wiita@ucsf.edu.; Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA.; Chan Zuckerberg Biohub, San Francisco, California, USA.; Parker Insitute for Cancer Immunotherapy, San Francisco, California, USA.
Source: Journal for immunotherapy of cancer [J Immunother Cancer] 2025 Dec 30; Vol. 13 (12). Date of Electronic Publication: 2025 Dec 30.
Publication Type: Journal Article
Journal Info: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Electronic Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41469141
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Affinity-matured CD72-targeting nanobody CAR T cells enhance elimination of antigen-low B-cell malignancies.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Izgutdina+A%22">Izgutdina A</searchLink>; Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Rashid+T%22">Rashid T</searchLink>; Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Temple+WC%22">Temple WC</searchLink>; Department of Pediatrics, Division of Oncology, UCSF Benioff Children's Hospital, University of California San Francisco, San Francisco, California, USA.; Department of Pediatrics, Division of Allergy, Immunology, and Bone Marrow Transplantation, UCSF Benioff Children's Hospital, University of California San Francisco, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Aminov+S%22">Aminov S</searchLink>; Department of Oncology, Blood Cancer Institute, Albert Einstein College of Medicine, Bronx, New York, USA.<br /><searchLink fieldCode="AU" term="%22Patiño-Escobar+B%22">Patiño-Escobar B</searchLink>; Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Walunj+S%22">Walunj S</searchLink>; Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Geng+H%22">Geng H</searchLink>; Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Takamatsu+H%22">Takamatsu H</searchLink>; Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA.; Department of Hematology, Kanazawa University, Kanazawa, Japan.<br /><searchLink fieldCode="AU" term="%22Gil-Alós+D%22">Gil-Alós D</searchLink>; Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA.; Hospital Universitario 12 de Octubre-Centro Nacional de Investigaciones Oncológicas (H12O-CNIO) Haematological Malignancies Clinical Research Unit, Spanish National Cancer Research Centre, Madrid, Spain.; Department of Hematology, Hospital Universitario 12 de Octubre-Universidad Complutense, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), CIBERONC, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Kang+AS%22">Kang AS</searchLink>; Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Ramos+E%22">Ramos E</searchLink>; Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Chen+SY%22">Chen SY</searchLink>; Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Johnson+H%22">Johnson H</searchLink>; Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Nix+MA%22">Nix MA</searchLink>; Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Naik+A%22">Naik A</searchLink>; Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Li+M%22">Li M</searchLink>; Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Yuan+CM%22">Yuan CM</searchLink>; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Wang+HW%22">Wang HW</searchLink>; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Sahu+S%22">Sahu S</searchLink>; Department of Oncology, Blood Cancer Institute, Albert Einstein College of Medicine, Bronx, New York, USA.<br /><searchLink fieldCode="AU" term="%22Larson+RC%22">Larson RC</searchLink>; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Carpenter+C%22">Carpenter C</searchLink>; Arc Institute, Palo Alto, California, USA.<br /><searchLink fieldCode="AU" term="%22Salangsang+F%22">Salangsang F</searchLink>; Preclinical Therapeutics Core, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Phojanakong+P%22">Phojanakong P</searchLink>; Preclinical Therapeutics Core, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Serrano+JAC%22">Serrano JAC</searchLink>; Preclinical Therapeutics Core, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Tariq+I%22">Tariq I</searchLink>; Preclinical Therapeutics Core, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Zakraoui+O%22">Zakraoui O</searchLink>; Preclinical Therapeutics Core, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Steri+V%22">Steri V</searchLink>; Preclinical Therapeutics Core, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Valeri+A%22">Valeri A</searchLink>; Hospital Universitario 12 de Octubre-Centro Nacional de Investigaciones Oncológicas (H12O-CNIO) Haematological Malignancies Clinical Research Unit, Spanish National Cancer Research Centre, Madrid, Spain.; Department of Hematology, Hospital Universitario 12 de Octubre-Universidad Complutense, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), CIBERONC, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Martinez-Lopez+J%22">Martinez-Lopez J</searchLink>; Hospital Universitario 12 de Octubre-Centro Nacional de Investigaciones Oncológicas (H12O-CNIO) Haematological Malignancies Clinical Research Unit, Spanish National Cancer Research Centre, Madrid, Spain.; Department of Hematology, Hospital Universitario 12 de Octubre-Universidad Complutense, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), CIBERONC, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Maus+MV%22">Maus MV</searchLink>; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA.; Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Parekh+S%22">Parekh S</searchLink>; Department of Medicine, Division of Hematology and Medical Oncology; Department of Oncological Sciences; and Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.<br /><searchLink fieldCode="AU" term="%22Verma+A%22">Verma A</searchLink>; Department of Oncology, Blood Cancer Institute, Albert Einstein College of Medicine, Bronx, New York, USA.<br /><searchLink fieldCode="AU" term="%22Shah+NN%22">Shah NN</searchLink>; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Wiita+AP%22">Wiita AP</searchLink>; Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA arun.wiita@ucsf.edu.; Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA.; Chan Zuckerberg Biohub, San Francisco, California, USA.; Parker Insitute for Cancer Immunotherapy, San Francisco, California, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101620585%22">Journal for immunotherapy of cancer</searchLink> [J Immunother Cancer] 2025 Dec 30; Vol. 13 (12). <i>Date of Electronic Publication: </i>2025 Dec 30.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22BMJ+Publishing+Group+Ltd%22">BMJ Publishing Group Ltd </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101620585 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2051-1426 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220511426%22">20511426 </searchLink><i>NLM ISO Abbreviation: </i>J Immunother Cancer <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41469141
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1136/jitc-2025-012013
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: Affinity-matured CD72-targeting nanobody CAR T cells enhance elimination of antigen-low B-cell malignancies.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Izgutdina A
      – PersonEntity:
          Name:
            NameFull: Rashid T
      – PersonEntity:
          Name:
            NameFull: Temple WC
      – PersonEntity:
          Name:
            NameFull: Aminov S
      – PersonEntity:
          Name:
            NameFull: Patiño-Escobar B
      – PersonEntity:
          Name:
            NameFull: Walunj S
      – PersonEntity:
          Name:
            NameFull: Geng H
      – PersonEntity:
          Name:
            NameFull: Takamatsu H
      – PersonEntity:
          Name:
            NameFull: Gil-Alós D
      – PersonEntity:
          Name:
            NameFull: Kang AS
      – PersonEntity:
          Name:
            NameFull: Ramos E
      – PersonEntity:
          Name:
            NameFull: Chen SY
      – PersonEntity:
          Name:
            NameFull: Johnson H
      – PersonEntity:
          Name:
            NameFull: Nix MA
      – PersonEntity:
          Name:
            NameFull: Naik A
      – PersonEntity:
          Name:
            NameFull: Li M
      – PersonEntity:
          Name:
            NameFull: Yuan CM
      – PersonEntity:
          Name:
            NameFull: Wang HW
      – PersonEntity:
          Name:
            NameFull: Sahu S
      – PersonEntity:
          Name:
            NameFull: Larson RC
      – PersonEntity:
          Name:
            NameFull: Carpenter C
      – PersonEntity:
          Name:
            NameFull: Salangsang F
      – PersonEntity:
          Name:
            NameFull: Phojanakong P
      – PersonEntity:
          Name:
            NameFull: Serrano JAC
      – PersonEntity:
          Name:
            NameFull: Tariq I
      – PersonEntity:
          Name:
            NameFull: Zakraoui O
      – PersonEntity:
          Name:
            NameFull: Steri V
      – PersonEntity:
          Name:
            NameFull: Valeri A
      – PersonEntity:
          Name:
            NameFull: Martinez-Lopez J
      – PersonEntity:
          Name:
            NameFull: Maus MV
      – PersonEntity:
          Name:
            NameFull: Parekh S
      – PersonEntity:
          Name:
            NameFull: Verma A
      – PersonEntity:
          Name:
            NameFull: Shah NN
      – PersonEntity:
          Name:
            NameFull: Wiita AP
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 30
              M: 12
              Text: 2025 Dec 30
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 2051-1426
          Numbering:
            – Type: volume
              Value: 13
            – Type: issue
              Value: 12
          Titles:
            – TitleFull: Journal for immunotherapy of cancer
              Type: main
ResultId 1